Definium Therapeutics Inc.
DFTX | NASDAQ
$36.33
$0.00 (0.00%)
Nov 2, 2026, 9:30 AM ET · Market open
Company Profile
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Robert Barrow | Chief Executive Officer & Director |
| Brandi L. Roberts | Chief Financial Officer |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary |
| Beth Calitri | Vice President of Corporate Communications |
| Daniel Rollings Karlin | Chief Medical Officer |
| Gitanjali Jain | VP & Head of Investor Relations |
| Leonard Latchman | Co-Founder |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations |
| Scott Freeman | Co-Founder & Clinical Advisor |
| Stephanie Fagan | Chief Corporate Affairs Officer |
Definium Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 15, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Robert Barrow |
Contact Details
One World Trade Center New York,
New York 10007 United States
Stock Details
| Ticker Symbol | DFTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001813814 |
| CUSIP Number | 24477V105 |
| ISIN Number | CA24477V1058 |
| SIC Code | 2833 |
Recent News
- 1 month ago / businesswire.comDefinium Therapeutics Announces New Employee Inducement Grants
- 1 month ago / marketbeat.comDefinium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
- 2 months ago / zacks.comDefinium Reports Second Phase III Success in Anxiety Disorder Program
- 2 months ago / gurufocus.comDefinium Therapeutics (DFTX) Achieves Positive Results in Phase 3 Study for DT120 ODT
- 2 months ago / benzinga.comDefinium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
- 2 months ago / businesswire.comDefinium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
- 2 months ago / seekingalpha.comDefinium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript
- 2 months ago / businesswire.comDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
- 3 months ago / benzinga.comThis Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- 3 months ago / marketbeat.comDefinium Therapeutics' DT120 Meets Phase III Goals in GAD Study
Add to Watchlist
Select watchlists to add or remove DFTX